EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 342 filers reported holding EXELIXIS INC in Q2 2021. The put-call ratio across all filers is 1.12 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $2,499 | -1.1% | 105,326 | 0.0% | 0.02% | -8.3% |
| Q4 2023 | $2,527 | +4.7% | 105,326 | -4.6% | 0.02% | 0.0% |
| Q3 2023 | $2,413 | +122.2% | 110,426 | +94.5% | 0.02% | +140.0% |
| Q2 2023 | $1,086 | +8.7% | 56,785 | +10.3% | 0.01% | 0.0% |
| Q1 2023 | $999 | +20.9% | 51,482 | 0.0% | 0.01% | +11.1% |
| Q4 2022 | $826 | -99.9% | 51,482 | +20.1% | 0.01% | +12.5% |
| Q3 2022 | $672,000 | -19.4% | 42,882 | +16.5% | 0.01% | 0.0% |
| Q1 2022 | $834,000 | +14.6% | 36,800 | -7.5% | 0.01% | +33.3% |
| Q4 2021 | $728,000 | -13.4% | 39,800 | 0.0% | 0.01% | -25.0% |
| Q3 2021 | $841,000 | +16.0% | 39,800 | 0.0% | 0.01% | +14.3% |
| Q2 2021 | $725,000 | -19.4% | 39,800 | 0.0% | 0.01% | -22.2% |
| Q1 2021 | $899,000 | +0.7% | 39,800 | -10.6% | 0.01% | 0.0% |
| Q4 2020 | $893,000 | -28.4% | 44,500 | -12.7% | 0.01% | -35.7% |
| Q3 2020 | $1,247,000 | +3.0% | 51,000 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $1,211,000 | +37.9% | 51,000 | 0.0% | 0.01% | +16.7% |
| Q1 2020 | $878,000 | -10.0% | 51,000 | -7.9% | 0.01% | +9.1% |
| Q4 2019 | $976,000 | -0.4% | 55,400 | 0.0% | 0.01% | -8.3% |
| Q3 2019 | $980,000 | -17.2% | 55,400 | 0.0% | 0.01% | -14.3% |
| Q2 2019 | $1,184,000 | -18.1% | 55,400 | -8.7% | 0.01% | -22.2% |
| Q1 2019 | $1,445,000 | +40.7% | 60,700 | +16.3% | 0.02% | +28.6% |
| Q4 2018 | $1,027,000 | +11.0% | 52,200 | 0.0% | 0.01% | +27.3% |
| Q3 2018 | $925,000 | +533.6% | 52,200 | -45.2% | 0.01% | +450.0% |
| Q3 2014 | $146,000 | -54.8% | 95,300 | 0.0% | 0.00% | -50.0% |
| Q2 2014 | $323,000 | -4.2% | 95,300 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $337,000 | -46.0% | 95,300 | -6.4% | 0.00% | -42.9% |
| Q4 2013 | $624,000 | +5.2% | 101,820 | 0.0% | 0.01% | +40.0% |
| Q3 2013 | $593,000 | +17.7% | 101,820 | -8.3% | 0.01% | 0.0% |
| Q2 2013 | $504,000 | – | 110,990 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
| GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
| Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
| CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
| EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
| CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
| Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
| Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |